Annexes to COM(2023)2 - EU position on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961 - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
| dossier | COM(2023)2 - EU position on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961. |
|---|---|
| document | COM(2023)2  |
| date | March 9, 2023 |
ANNEX
Position to be taken by the Member States which are members of the Commission on Narcotic Drugs, acting jointly in the interest of the Union during the 66th session of the Commission on Narcotic Drugs, which takes place from 13 to 17 March 2023, on the scheduling of substances:
| (1) | ADB-BUTINACA is to be included in Schedule II of the Convention on Psychotropic Substances. |
| (2) | Protonitazene is to be included in Schedule I of the Convention on Narcotic Drugs. |
| (3) | Etazene is to be included in Schedule I of the Convention on Narcotic Drugs. |
| (4) | Etonitazepyne is to be included in Schedule I of the Convention on Narcotic Drugs. |
| (5) | 2-methyl-AP-237 is to be included in Schedule I of the Convention on Narcotic Drugs. |
| (6) | Alpha-PiHP is to be included in the Schedule II of the Convention on Psychotropic Substances. |
| (7) | 3-MMC is to be included in the Schedule II of the Convention on Psychotropic Substances. |